Comparative Pharmacology
Head-to-head clinical analysis: MAXZIDE versus VASERETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXZIDE versus VASERETIC.
MAXZIDE vs VASERETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxzide is a combination of triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal renal tubule, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule. The combination reduces electrolyte disturbances.
Vaseretic is a combination of enalapril maleate (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide diuretic). Enalapril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and chloride excretion by inhibiting the Na+-Cl- symporter in the distal convoluted tubule, leading to diuresis and vasodilation.
Hydrochlorothiazide 25 mg / triamterene 37.5 mg orally once daily; may increase to twice daily if needed. Max dose: hydrochlorothiazide 50 mg / triamterene 75 mg daily.
One tablet (10 mg enalapril maleate/25 mg hydrochlorothiazide) orally once daily; may increase to 2 tablets daily if needed.
None Documented
None Documented
Triamterene: terminal half-life is approximately 4-6 hours in healthy individuals, but may be prolonged in renal impairment. Hydrochlorothiazide: terminal half-life is approximately 6-15 hours, and it accumulates in renal dysfunction. The combination product's effective half-life is influenced by both components.
Enalaprilat: 35–38 hours (terminal). Clinically, effective half-life ~11 hours. Prolonged in renal impairment (CrCl <30 mL/min: up to 60 hours).
Renal: triamterene and hydrochlorothiazide are primarily excreted by the kidneys. Triamterene is extensively metabolized; about 20-30% of the dose is excreted unchanged in urine, with additional metabolites. Hydrochlorothiazide is excreted unchanged in urine (at least 61% of an oral dose within 24 hours).
Renal: 60% (enalaprilat); biliary/fecal: 33% (enalaprilat). Unchanged enalapril: <5% in urine.
Category C
Category C
Diuretic Combination
ACE Inhibitor/Diuretic Combination